Navigation Links
Techne Corporation Declares Dividend And Announces An Increase In Its Share Repurchase Program
Date:10/25/2012

MINNEAPOLIS, Oct. 25, 2012 /PRNewswire/ -- Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.30 per share for the quarter ended September 30, 2012.  The quarterly dividend will be payable November 19, 2012 to all common shareholders of record on November 5, 2012.  Future cash dividends will be considered by the Board of Directors on a quarterly basis.

Techne's Board of Directors also authorized the repurchase of an additional $100 million of the Company's common stock in connection with its ongoing share repurchase program, which does not have an expiration date.  Including the above amount, the total share repurchase authorization remaining is approximately $127 million.  Repurchases under the program will be at the discretion of management and may be made in open market, pursuant to one or more 10b5-1 plans, structured transactions, privately negotiated transactions or otherwise, from time to time, depending on market conditions.  The stock repurchase program may be modified or discontinued at any time.  The share repurchase will be funded with a portion of the Company's existing cash and available-for-sale investments.

Techne Corporation has two operating subsidiaries:  Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty manufacturer of biological products.  R&D Systems has three operating subsidiaries, BiosPacific, Inc. (BiosPacific), located in Emeryville, California, Boston Biochem, Inc., located in Cambridge, Massachusetts and R&D Systems China Co. Ltd., (R&D China), located in Shanghai, China.  BiosPacific is a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems and immunodiagnostic kits.  Boston Biochem is a leading developer of ubiquitin-related research products.  R&D China and R&D Europe distribute biotechnology products.  R&D Europe has two subsidiaries, Tocris Holding, Ltd (Tocris) of Bristol, England and R&D Systems GmbH, a German sales operation.  Tocris is a leading supplier of reagents for non-clinical life science research.


'/>"/>
SOURCE Techne Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Techne Corporation Declares Dividend
2. United Therapeutics Corporation To Announce Third Quarter 2012 Financial Results Before Market Open On Thursday, November 1, 2012
3. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
4. Neogen Corporation Announces 1st Quarter Results Conference Call
5. China Cord Blood Corporation and Golden Meditech Holdings Limited Enter into Convertible Note Financing to Further Expand Cord Blood Banking Services
6. Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
7. Bluechiip Signs Strategic Partnership with Gentris Corporation
8. China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2013
9. China Cord Blood Corporation to Report First Quarter of Fiscal 2013 Financial Results
10. China Cord Blood Corporation and Cordlife Group Limited Foster Closer Alliance Across Asia
11. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... ... market news outlet had provided a research update on Aytu Bioscience and cited ... product. , According to Soulstring, prescription rates for Natesto® have more than doubled ...
(Date:8/16/2017)... ... 16, 2017 , ... Tunnell Consulting announced today that four of ... Annual Meeting and Expo , to be held October 29 through November 1 in ... innovation to advance patient therapies.” , The ISPE Annual Meeting and Expo will feature ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... a different cell type. Many treatments for specific cancers, such as breast, prostate, ... targeted treatment is androgen deprivation therapy for advanced prostate cancer. , This ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... beneficial microbe delivery system, announced it has secured $2M in funding from an ... City Angels, Carmen Innovations, and SVG Thrive Fund. With this investment, 3Bar is ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
Breaking Biology News(10 mins):